AI assistant
Sending…
Dermata Therapeutics, Inc. — Director's Dealing 2021
Sep 2, 2021
35467_dirs_2021-09-01_e3482ac6-bf9e-4b96-9e76-731285f75f28.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Dermata Therapeutics, Inc. (DRMA)
CIK: 0001853816
Period of Report: 2021-09-01
Reporting Person: Van Hoose Kyri K. (Chief Financial Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-09-01 | Stock Option (right to Buy) | $5.39 | A | 75000 | Acquired | 2031-09-01 | Common Stock (75000) | Direct |
Footnotes
F1: The option vests in 48 equal monthly installments commencing October 1, 2021.
More from Dermata Therapeutics, Inc.
Regulatory Filings
2026
Jun 4
Capital/Financing Update
2026
May 29
Declaration of Voting Results & Voting Rights Announcements
2026
May 27
Share Issue/Capital Change
2026
May 22
Annual Report
2026
Apr 17
Proxy Solicitation & Information Statement
2026
Apr 17
Director's Dealing
2026
Mar 17
Board/Management Information
2026
Feb 25
Major Shareholding Notification
2026
Feb 18
Major Shareholding Notification
2026
Feb 17